TransMedics (TMDX) Equity Average (2018 - 2026)

TransMedics has reported Equity Average for 9 years, with the latest figure at $483.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 95.41% year-over-year to $483.6 million; the trailing twelve-month figure through Mar 2026 stood at $483.6 million (up 95.41% YoY), and the FY2025 full-year result was $350.9 million, up 91.82% from the prior year.
• Equity Average for Q1 2026 stood at $483.6 million, up from $414.2 million in the prior quarter.
• The five-year high for Equity Average was $483.6 million in Q1 2026, with the low at $55.4 million in Q2 2022.
• Average Equity Average over 5 years is $209.9 million, with a median of $187.6 million recorded in 2022.
• Year-over-year, Equity Average plunged 40.62% in 2022 and surged 204.83% in 2023.
• Tracing TMDX's Equity Average over 5 years: stood at $187.6 million in 2022, then retreated by 29.73% to $131.8 million in 2023, then jumped by 66.32% to $219.3 million in 2024, then soared by 88.88% to $414.2 million in 2025, then advanced by 16.76% to $483.6 million in 2026.
• The last three Equity Average figures came in at $483.6 million (Q1 2026), $414.2 million (Q4 2025), and $336.7 million (Q3 2025), per Business Quant data.

Peer Comparison